Curriculum Vitae

Rosanna Tarricone is Associate Professor of the Department of Policy Analysis and Public Management at Bocconi University. Since January 2017, she is Associate Dean for Government, Health and Not for Profit Division.

At SDA Bocconi, she was first Co-director, and then, Director of Master MIHMEP from 2002 to 2011. She works on numerous researches and training projects for several key actors of the pharmaceutical and medical device industries and for public institutions. 

Her research activities focus on economic evaluation analysis of healthcare programmes, health policy, healthcare management, health technology assessment, health economics and budget impact analysis. She has been PI of a European funded project - MedtecHTA: Methods for Health Technology Assessment of Medical Devices: A European Perspective.

She authored numerous books and articles on prestigious journals such as Social Science & Medicine, Health Economics, Value in Health and Health Policy, among others. She is member of the Board of Directors of ISPOR (International Society of Outcome Research), active member of iHEA (international Health Economics Association), and HTAi (Health Technology Assessment international). She has been the Director of the Economic Affairs Department at Eucomed and Scientific Director of the European Health Technology Institute for Socio-Economic Research. Rosanna is member of the Board of Directors of the “San Matteo” Hospital Trust.

Rosanna earned a Degree in Business Administration from Bocconi University, an MSc in Health Services Management and a Ph.D. in Public Health and Policy from the London School of Hygiene and Tropical Medicine, University of London.



  • R. Tarricone (a cura di), Politiche per la salute e scelte aziendali. Impatto sull’innovazione e diffusione delle tecnologie mediche, EGEA, 2012
  • R. Tarricone, Innovazione e competitività dei sistemi industriali regolati. Le imprese dei dispositivi medici, EGEA, 2010
  • R. Tarricone, A. Tsouros, Homecare in Europe, World Health Organisation, 2008
  • R. Tarricone, Valutazioni economiche e management in sanità. Applicazioni ai programmi e tecnologie sanitarie, Milano, McGraw-Hill, 2004


  • Generali D, Venturini S, Rognoni C, Ciani R, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A Network Meta-Analysis of Everolimus plus Exemestane versus Chemotherapy in the First and Second Line Treatment of Estrogen Receptor Positive Metastatic Breast Cancer. Breast Cancer Research and Treatment 2015;5 June. Published online (DOI 10.1007/s10549-015-3453-9)
  • Gonzales FM, Finch AP, Armeni P, Boscolo PR, Tarricone R. Comparative Effectiveness of Mitraclip versus Optimal Medical Therapy in High-Risk Surgical Patients: a Comprehensive Review. Expert Review of Medical Devices 2015 (accepted for publication on May 21st
  • Beresniak A, Medina-Lara A, Auraye JP, Weverf A, Praetf JC, Tarricone R, Torbica A, Dupont D, Lamure M, Durue G. Validation of the underlining assumptions of the QALY outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 2015;33(1):61-69
  • Gehring M, Jommi C, Tarricone R, Cirenei M, Ambrosio G. Towards a More Competitive Italy in Clinical Research: The Survey of Attitudes towards Trial sites in Europe (The SAT-EU StudyTM). Epidemiology, Biostatistics and Public Health 2014. Published online 2015;12:1
  • Sommariva S, Tarricone R, Lazzeri M, Ricciardi W, Montorsi F. Prognostic value of CCP score in patients with prostate cancer: a systematic review and meta-analysis. European Urology (accepted on 2014, November 19th)
  • Tarricone R, Torbica A, Ferrè F, Drummond M. Generating Appropriate Clinical Data for Value Assessment of Medical Devices: What Role Does Regulation Play? Expert Review of Pharmacoeconomics and Outcome Research 2014;14(5):707-718
  • A. Compagni, A. Melegaro, R. Tarricone. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. Italian Journal of Public Health 2012;9:s36-s45
  • R. Tarricone, A. Torbica. Costing and performance in healthcare management. Faltin, F.W, Kenett, R.S., Ruggeri, F. (a cura di) Statistical methods in healthcare. Wiley, UK, 2012, pp.386-404
  • G. Callea, R. Tarricone, A. Medina Lara. Economic evidence of interventions for acute myocardial infarction: a review of the literature. EUROINTERVENTION 2012;8:P71-P76
  • R. Mujica-Mota, R. Tarricone, O. Ciani, J.F.P. Bridges, M. Drummond. Determinants of demand for total hip and and knee arthroplasty: a systematic literature review. BMC Health Services Research 2012;12:225-257
  • O. Ciani, R. Tarricone, A. Torbica. Diffusion and use of Health Technology Assessment in policy making: what lessons for decentralised healthcare systems? Health Policy, 2012
  • R. Tarricone. Setting the Scene: The Challenges of Universal Health Coverage and the Contribution of Management Education. Value in Health, 2012
  • M. Drummond, R. Tarricone, A. Torbica. Assessing the added value of health technologies: reconciling different perspectives. Value in Health, 2012
  • R. Tarricone, G. Valotti. Il miglioramento del performance management nelle aziende sanitarie pubbliche: oltre le mode e le tradizioni. Autori Vari (a cura di) Strategia e performance management nelle aziende sanitarie pubbliche. EGEA, 2012, pp.107-110
  • P. Armeni, O. Ciani, V.A. Vella, M.C. Cavallo, R. Tarricone. I Dispositivi medici in Italia: un settore, tanti mercati. MECOSAN 2012:65-81
  • A. Compagni, A. Melegaro, R. Tarricone. Systematic review of the economic literature on genetic testing for the prevention of venous thromboembolism. Italian Journal of Public Health 2012;9:s36-s45
  • R. Tarricone, M. Drummond. Challenges in the clinical and economic evaluation of medical devices: the case of transcathether aortic valve implantation. Journal of Medical Marketing 2012;11:221-229
  • P. Armeni, O. Ciani, R. Tarricone, I. Palla, F. Pierotti, G. Turchetti. PDTA per la chirurgia bariatrica: l'esperienza di 6 centri italiani. MECOSAN 2011;79:9-22
  • R. Tarricone. Pharmaco-economics and decision making in health care. The case of “extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis”. Internal and Emergency Medicine 2011;6:581-582
  • C Sorenson, R Tarricone, M Siebert, M Drummond. Applying Health Economics for Policy Decision Making: Do Devices Differ From Drugs?. EUROPACE 2011;13:ii54-ii58
  • R. Tarricone. Innovazione e competitività dei sistemi industriali regolati. le imprese dei dispositivi medici. EGEA, 2010
  • MC Cavallo, O Ciani, A Gugiatti, C Jommi, R Tarricone. La gestione dell'innovazione tecnologica in sanità. Analisi e confronto di alcune politiche regionali in Italia. MECOSAN 2010;74:37-65
  • R. Tarricone, A. Torbica, F. Franzetti, V.D. Rosenthal. Hospital cost of central line-associated bloodstream infections and cost-effectiveness of closed vs. open infusion containers. The case of Intensive Care Units in Italy. Cost Effectiveness and Resource Allocation 2012;8:1-10
  • Aguzzi G, Bartoli S, Tarricone R. Systematic review of urinary incontinence and overactive bladder cost-of-illness studies. The Open Pharmacoeconomics & Health Economics Journal 2010;2:11-24
  • Bartoli S, Aguzzi G, Tarricone R. Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review. UROLOGY 2010;75:491-500
  • R. Tarricone, C. Giaquinto, N. Largeron, M. Trichard. Analisi economica dei costi e dei benefici dell’implementazione di un programma di prevenzione antirotavirus con il vaccino pentavalente in Italia. Pharmacoeconomics Italian Research Articles 2009; 11(1): 1-13
  • A. Torbica, R. Tarricone, S. Calciolari, V. Branca, SM Gaini. Analisi dei costi del trattamento dell’aneurisma intracranico in Italia. Pharmacoeconomics Italian Research Articles 2009; 11(1): 25-37
  • M. Drummond, A. Griffin, R. Tarricone. Economic evaluation for devices and drugs. Same or different? Value in Health 2009; 12(4):402-404
  • G. Fattore, MC Cavallo, R. Tarricone. Lo sviluppo dell’Health Technology in Italia: contenuti, approcci e riferimenti internazionali. In Rapporto OASI 2008. L’aziendalizzazione della sanità in Italia. EGEA, 2008
  • R. Tarricone, G. Aguzzi, A. Capone, et al. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. Journal of Medical Economics 2008; 11:265-279
  • R. Tarricone, G. Aguzzi, F. Musì, L. Fariselli, A. Casasco. Cost-effectiveness for trigeminal neuralgia: Cyberknife vs microvascular decompression. Neuropsychiatric Disease and Treatment 2008; 4(3):647-652
  • Roggero P, Tarricone R, Mangiaterra V, et al.  What do people think about disabled youth and employment in developing and developed countries? Results from an e-discussion hosted by the World Bank. Disability and Society 2006;21(6):645-650
  • Tarricone R. COI analysis: what room in health economics? Health Policy 2006;77(1):51-63
  • Tarricone R, Girolami F. Economic evaluation of a new antiemetic drug: palonosetron vs ondansetron. Clinical Drug Investigation 2005; 25(9):597-608
  • Gerzeli S, Tarricone R, Zolo P, et al. The economic burden of stroke in Italy. The EcLIPSE Study: Economic Longitudinal Incidence-based Project for Stroke Evaluation. Neurological Science 2005; 26(2):72-80
  • Otto M., Fricke F.U.,Tarricone R., "Analisi costi-efficacia della cura del dolore in Italia: la radioisotopoterapia con Samario-153 e la terapia convenzionale", Mecosan, 2004, n. 52: 41-50
  • Heller B, Tarricone R. Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Current Medical Research and Opinion 2004;20(8):1279-1290
  • Tarricone R., "L'analisi di costo sociale. Quale ruolo per il management e l'economia sanitaria?", Mecosan, 2004, n. 50: 49-68
  • Gillette JA, Tarricone R. Economic Evaluation of osteoarthritis treatment in Europe. Expert Opinion 2003; 4(3):327-341
  • Tarricone R., Martelli E., Parazzini F., Darbà J., Le Pen C., Rovira J., "Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in France, Italy and Spain". Clinical Drug Investigation 2001;21(7): 453-464
  • Tarricone R., "Valutazione di convenienza economica comparata tra quetiapina e risperidone nel trattamento della schizofrenia", Pharmacoeconomics Italian research Articles, 2001, n. 3(1): 27-36
  • Fattore G., Gerzeli S., Tarricone R., "The costs of farmacological treatment for major depression. The Italian prospective multi-centre observational incidence-based study", Pharmacoeconomics, 2000, n. 2: 167-174
  • Tarricone R, Gerzeli S, Montanelli R, Frattura L, Percudani M, Racagni G. Direct and indirect costs of Schizophrenia in community psychiatric services in Italy. The GISIES study. Health Policy 2000; 51:1-18
  • Colangelo I., Gerzeli S.,Tarricone R., "I costi ospedalieri dell’ictus in Italia: un confronto tra diversi modelli di cura", Mecosan, 2000, n. 38: 27-36
  • Busca MR, Negrini C, Cuccurullo C, Tarricone R, Gerzeli S, Gandolfo C, Zolo P. Terapia dell’ictus: valutazione economica e modelli organizzativi. Argomenti di Neurologia 2000;10(2):75-79
  • Inglese L, Graziani L, Tarricone R. Il trattamento percutaneo delle arteriopatie ostruttive periferiche: i perché di una scelta. Ital Heart J Suppl 2000; 1(9):1138-1147
  • Tabacchi M.,Tarricone R., "Il programma regionale di sviluppo: il caso della Lombardia", Mecosan, 1998, n. 25: 53-62
  • Tarricone R., Tabacchi M., "Un'analisi di convenienza economica comparata: il trattamento dell'osteoartrosi e dell'artrite reumatoide con Farmaci Antiinfiammatori Non-Steroidei", Mecosan, 1998, n. 25: 53-62 
  • Montanelli R.,Tarricone R., "Il costo sociale della schizofrenia. Una rassegna ragionata della bibliografia", Mecosan, 1997, n. 21: 21-31
  • Tarricone R., "Metodologia di indagine e primi risultati sul costo sociale della depressione maggiore in Italia (GISIED)", Mecosan, 1997, n. 22: 57-68
  • Tarricone R., Fattore G., Percudani M., Recchia M., Serra G., Taddei C., "I costi dell'assistenza ospedaliera nella depressione maggiore: risultati di uno studio osservazionale multicentrico", Rivista di Psichiatria, 1997, n. 32 (5): 189-197 
  • Tarricone R., Mantovani L., Montanelli R., "Valutazione economica dell'uso di Gas Plasma di perossido di idrogeno nella sterilizzazione in ambito ospedaliero", Mecosan, 1997, n. 20: 34-45 
  • Cavallo C, Tarricone R. La valutazione del costo sociale delle malattie. Mecosan, 1996; 17: 8-16
  • Tarricone R, Bertolini F, Grazioli I, Saggioro A. Valutazione economica della prevenzione con Misoprostol della gastropatia da farmaci anti-infiammatori non steroidei in Italia. Argomenti di Gastroenterologia Clinica, 1994; 7 (7): 263-269
  • Tarricone R. Valutare il costo di una malattia. Prospettive Sociali e Sanitarie 1994; 19: 1-6
  • Tarricone R., "Il sistema assicurativo sanitario olandese", Mecosan, 1994, n. 10: 98-110 
  • Fattore G, Meneguzzo M, Tarricone R. Proposta di finanziamento del programma Medicare dell'Oregon. Mecosan, 1993; 5: 105-117
  • Borgonovi E., Tarricone R., "Stima dei costi sanitari dell'ischemia critica cronica degli arti", Annali Italiani di Medicina Interna, 1993, n. 8 (suppl): 81-84 
  • Tarricone R, Aspetti critici del sistema di riordino del Servizio Sanitario Nazionale. Mecosan, 1992; 3: 150-151